Journal article
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism.
METHODS: In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional therapy (subcutaneous enoxaparin, followed by warfarin) in 5395 patients with acute venous thromboembolism. The primary efficacy outcome was …
Authors
Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Masiukiewicz U; Pak R; Thompson J; Raskob GE
Journal
New England Journal of Medicine, Vol. 369, No. 9, pp. 799–808
Publisher
Massachusetts Medical Society
Publication Date
August 29, 2013
DOI
10.1056/nejmoa1302507
ISSN
0028-4793